



The Board of Oasmia Pharmaceutical AB's proposal to the annual general meeting on 26 September 2019 (Item 17)

Resolution on issue authorization

The Board proposes that the general meeting resolve on issue authorization as follows.

The general meeting authorises the Board to, on one or several occasions during the period up until the next annual general meeting, resolve on one or more issues of shares, warrants and/or convertible instruments. The Board shall be authorized to adopt decisions on an issue of shares, warrants and/or convertible instruments with or without deviation from the shareholders' preemption rights. The issue resolution may be an issue in kind or an issue by way of set-off and/or on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1-3 and 5, of the Swedish Companies Act. The new shares, warrants and/or convertible instruments shall, in the event of a deviation from the shareholders' pre-emption rights, be issued at a subscription price based on the share price at the time of the issue (or in case of warrants or convertibles, with the share price as basis for a market valuation), decreased by any discount in line with market practice that the Board deems necessary. All other terms are decided by the Board, but shall be in line with market practice. A maximum of 62 million shares may be issued under the authorization (including any new shares following the exercise or conversion of warrants and convertible bonds issued under the authorization).

A resolution in accordance with the Board's proposal requires that it is supported by shareholders holding not less than two-thirds of both the votes cast and the shares represented at the general meeting.